<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19045" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biological Weapon Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hayoun</surname>
            <given-names>Michael A.</given-names>
          </name>
          <aff>Tristar Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chen</surname>
            <given-names>Richard J.</given-names>
          </name>
          <aff>Jefferson-Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Swinkels</surname>
            <given-names>Helena M.</given-names>
          </name>
          <aff>University of British Columbia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>King</surname>
            <given-names>Kevin C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Hayoun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Chen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Helena Swinkels declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kevin King declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19045.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Biological weapons can be used in bioterrorism, biowarfare, or biocrime and include bacteria, viruses, fungi, and toxins; some agents are lethal, and others cause illness or incapacitation. Directing biological weapons at the human population, crops, and livestock often involves dispersing them as aerosols for easier spread. People or vectors can spread agents through ingestion, direct contact, or other methods. This activity reviews the most common agents and the evaluation and treatment of their resulting illnesses.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify clinical syndromes&#x000a0;that can be caused by biological agents,&#x000a0;including bacteria, viruses, fungi, and toxins.&#x000a0;</p></list-item><list-item><p>Differentiate between naturally occurring diseases and those caused by biological weapons by using standard diagnostic clues and epidemiological patterns.&#x000a0;</p></list-item><list-item><p>Select appropriate therapies and antimicrobial agents for specific biological&#x000a0;weapon agent-related illnesses.</p></list-item><list-item><p>Collaborate with other healthcare providers, first responders, and public health agencies to enhance preparedness and response to biological weapon-related incidents.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19045&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19045">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19045.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Biological weapons are agents, including bacteria, viruses, fungi, and toxins, used for malicious purposes: in war (biowarfare), to cause terror (bioterrorism), or for criminal acts (biocrime). [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/eis/field-epi-manual/chapters/Biologic-Toxic-Agents.html">Suspected Intentional Use Of Biologic And Toxic Agents. 2018</ext-link>] Some agents are lethal, and others cause illness or incapacitation. Entities direct biological agents at the human population, crops, and livestock. More than 180 pathogens and biotoxins have been researched or employed as biological weapons, including those that cause anthrax, tularemia, brucellosis, plague, Legionnaire disease, Q fever, glanders, melioidosis, smallpox, viral hemorrhagic fevers, influenza, coccidiosis, rice blast, and wheat rust. Biotoxins include ricin, botulinum toxin, and staphylococcal enterotoxin B. Designers create biological weapons to disperse as aerosols, facilitating rapid spread across large populations. However, agents may also spread from person to person or by vectors, ingestion, direct contact, or other methods.</p>
        <p>&#x000a0;Agents used for biological weapons have distinct advantages over conventional agents (eg, chemical weapons):</p>
        <list list-type="bullet">
          <list-item>
            <p>Microbial agents are often more easily mass-produced</p>
          </list-item>
          <list-item>
            <p>Large quantities are easy to conceal and transport</p>
          </list-item>
          <list-item>
            <p>Agents are more easily able to become airborne or waterborne, increasing the area of dissemination</p>
          </list-item>
          <list-item>
            <p>Some agents pass from person to person</p>
          </list-item>
        </list>
        <p>
<bold>Classification</bold>
</p>
        <p>Biological agents are classified into different categories depending on their ability to cause illness and their impact on public health. The United States Centers for Disease Control and Prevention (CDC) categorizes agents into 3 groups:<xref ref-type="bibr" rid="article-19045.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Category A</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Highest priority</p>
              </list-item>
              <list-item>
                <p>Easily disseminated or transmitted</p>
              </list-item>
              <list-item>
                <p>High mortality rates and potential for major public health impact</p>
              </list-item>
              <list-item>
                <p>Can cause public panic and social disruption</p>
              </list-item>
              <list-item>
                <p>Require specific actions for public health preparedness</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Category B</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Second highest priority</p>
              </list-item>
              <list-item>
                <p>Moderately easy to disseminate</p>
              </list-item>
              <list-item>
                <p>Moderate morbidity and low mortality</p>
              </list-item>
              <list-item>
                <p>Require specific enhancements to the CDC's diagnostic and disease surveillance capacities</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p>Category C</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Third highest priority</p>
              </list-item>
              <list-item>
                <p>Potentially engineered for mass dissemination</p>
              </list-item>
              <list-item>
                <p>Potential for high morbidity and mortality and significant health impact</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>Category A agents include&#x000a0;<italic toggle="yes">Bacillus anthracis&#x000a0;</italic>(anthrax),&#x000a0;<italic toggle="yes">Clostridium botulinum</italic>&#x000a0;toxin (botulism),&#x000a0;<italic toggle="yes">Yersinia pestis&#x000a0;</italic>(plague),&#x000a0;<italic toggle="yes">Variola major&#x000a0;</italic>(smallpox),&#x000a0;<italic toggle="yes">Francisella tularensis&#x000a0;</italic>(tularemia), and viruses that cause hemorrhagic fevers (eg,&#x000a0;Ebola virus,&#x000a0;Marburg virus,&#x000a0;Lassa virus). Category B agents include&#x000a0;Brucella&#x000a0;species (Brucellosis),&#x000a0;<italic toggle="yes">Chlamydia psittaci&#x000a0;</italic>(Psittacosis),&#x000a0;<italic toggle="yes">Coxiella burnetii&#x000a0;</italic>(Q fever), ricin toxin (from&#x000a0;<italic toggle="yes">Ricinus communis</italic>), enteric pathogens (Salmonella<italic toggle="yes">, Escherichia coli O157:H7, </italic>Shigella), Staphylococcal enterotoxin B, and viruses that cause encephalitis. Category C agents are emerging pathogens such as Nipah virus and hantavirus.<xref ref-type="bibr" rid="article-19045.r1">[1]</xref></p>
      </sec>
      <sec id="article-19045.s3" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>In the absence of a declared or witnessed biological attack, early indications of biological weapon use are generally nonspecific. Healthcare personnel should be alert for unusual or unexpected illnesses or illness patterns. CDC guidelines provide diagnostic clues that may be helpful for the early identification of potential biological agent release:<xref ref-type="bibr" rid="article-19045.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Large numbers of ill persons with similar diseases/symptoms</p>
          </list-item>
          <list-item>
            <p>Unusual temporal or geographic clustering of illnesses (eg, persons attended the same event, a large number of cases uncommon to a given region)</p>
          </list-item>
          <list-item>
            <p>Unusual age distribution (eg, common childhood illness presenting in the adult population)</p>
          </list-item>
          <list-item>
            <p>Unusually high morbidity or mortality associated with common diseases</p>
          </list-item>
        </list>
        <p>Treatment may involve medications, post-exposure immunizations, or only supportive care.</p>
        <p>When a biological attack is suspected, illness, transmission prevention, and healthcare capacity are important considerations. Depending on the biological warfare agent involved, person-to-person transmission may occur. Post-exposure immunizations or prophylactic medications prevent certain toxicities. The use of agents capable of causing severe illness and death may quickly cause healthcare resources to be overwhelmed with patients requiring critical care and life-saving interventions. A large number of asymptomatic or mildly symptomatic patients may seek medical care. Detection of a biological attack, identifying the agents used, and determining the at-risk population are vital to incident and patient management.<xref ref-type="bibr" rid="article-19045.r2">[2]</xref><xref ref-type="bibr" rid="article-19045.r3">[3]</xref><xref ref-type="bibr" rid="article-19045.r4">[4]</xref><xref ref-type="bibr" rid="article-19045.r5">[5]</xref><xref ref-type="bibr" rid="article-19045.r6">[6]</xref><xref ref-type="bibr" rid="article-19045.r7">[7]</xref><xref ref-type="bibr" rid="article-19045.r8">[8]</xref></p>
      </sec>
      <sec id="article-19045.s4" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Anthrax</bold>
</p>
        <p>Anthrax infection can occur due to environmental or animal exposure (eg, "woolsorter disease") or to bioterrorism.&#x000a0;<italic toggle="yes">Bacillus anthracis</italic>&#x000a0;is a zoonotic, gram-positive, rod-shaped bacteria existing in the environment as an endospore. Infection occurs when spores germinate in host macrophages; as few as 2500 spores may cause infection. Four clinical forms exist based on the portal of entry: cutaneous, gastrointestinal, inhalational, and injectional.<xref ref-type="bibr" rid="article-19045.r9">[9]</xref><xref ref-type="bibr" rid="article-19045.r10">[10]</xref>&#x000a0;Mortalities are estimated to be 1%, 25% to 60%, 46%, and 33%, respectively.<xref ref-type="bibr" rid="article-19045.r10">[10]</xref>&#x000a0;<italic toggle="yes">B anthracis</italic>&#x000a0;causes gastrointestinal and inhalational anthrax infection when used as a bioweapon.&#x000a0;</p>
        <p>Gastrointestinal anthrax results from ingesting spore-contaminated meat, with an incubation period of 1 to 6 days.<xref ref-type="bibr" rid="article-19045.r11">[11]</xref>&#x000a0;Gastrointestinal anthrax has oropharyngeal and intestinal forms. Oropharyngeal infection results from spores settling in the pharyngeal area, resulting in localized ulceration, fever, and neck swelling. In intestinal anthrax, infection results in ulcerations in the small intestine, mesenteric lymphadenopathy, and ascites, possibly leading to bowel obstruction and perforation.<xref ref-type="bibr" rid="article-19045.r11">[11]</xref>&#x000a0;Both types of gastrointestinal anthrax are typically complicated by shock.&#x000a0;</p>
        <p>After an incubation period of about 4 days, the clinical course of inhalational anthrax is biphasic, first presenting as flu-like symptoms lasting about 4 days.<xref ref-type="bibr" rid="article-19045.r10">[10]</xref>&#x000a0;Without treatment, patients can rapidly deteriorate with respiratory distress, refractory shock, and death within 24 hours. A classic diagnostic finding is hemorrhagic mediastinitis, seen as a widened mediastinum on chest radiography.<xref ref-type="bibr" rid="article-19045.r10">[10]</xref>&#x000a0;</p>
        <p>A case is confirmed as anthrax by a compatible clinical picture with at least 2 supportive tests such as culture, serology, and real-time polymerase chain reaction (PCR). Standard barrier and contact precautions for patients with draining lesions are adequate, as anthrax does not spread from person to person.<xref ref-type="bibr" rid="article-19045.r12">[12]</xref>&#x000a0;As a nationally notifiable disease, it must be reported to public health officials. Infected human and animal remains should be burned.<xref ref-type="bibr" rid="article-19045.r12">[12]</xref></p>
        <p>The resilience of the spores to killing and the general ease of laboratory growth make anthrax a dangerous biological weapon.<xref ref-type="bibr" rid="article-19045.r13">[13]</xref>&#x000a0;Strains of weaponized anthrax may be penicillin-resistant.</p>
        <p>Treat patients with suspected, possible, or confirmed meningitis due to anthrax with multiple antibiotics: a fluoroquinolone (eg, ciprofloxacin) plus a B-lactam (eg, meropenem) or penicillin as bactericidal agents, plus a protein synthesis inhibitor (eg, Linezolid).<xref ref-type="bibr" rid="article-19045.r14">[14]</xref><xref ref-type="bibr" rid="article-19045.r12">[12]</xref>&#x000a0;Once meningitis is excluded, antibiotics can be adjusted.<bold>&#x000a0;</bold>Postexposure prophylaxis (PEP) consists of 42 to 60 days of oral ciprofloxacin or doxycycline plus 3 doses of subcutaneous anthrax vaccine absorbed (AVA) at 0, 2, and 4 weeks.<xref ref-type="bibr" rid="article-19045.r14">[14]</xref><xref ref-type="bibr" rid="article-19045.r12">[12]</xref>&#x000a0;PEP can be started at diagnosis of illness if not given previously.<bold>&#x000a0;</bold></p>
        <p>
<bold>Plague</bold>
</p>
        <p><italic toggle="yes">Yersinia pestis</italic>, a gram-negative, aerobic, non-spore-forming coccobacillus, causes the plague. The plague has been responsible for multiple pandemics and epidemics, notably killing over 25 million people in 14th-century Europe during the "black death."<xref ref-type="bibr" rid="article-19045.r15">[15]</xref>&#x000a0;Plague is usually transmitted from rodent reservoirs to humans by the bite of flea vectors.&#x000a0;<italic toggle="yes">Yersinia pestis&#x000a0;</italic>was used as a biological weapon in World War II when the Imperial Japanese dropped plague-contaminated rice and fleas into Chuhsien, China, resulting in an outbreak.<xref ref-type="bibr" rid="article-19045.r15">[15]</xref>&#x000a0;</p>
        <p>Plague presents in 3 clinical variants.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bubonic plague is the most common. Patients develop fevers, abdominal pain, and headaches. The rapid proliferation of bacteria in lymph nodes causes painful "buboes" in the groin, axillary, and cervical regions. Bubonic plague can develop into pneumonic or septicemic plague if not recognized and treated in time.&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pneumonic plague presents a nonspecific flu-like illness that progresses to severe hemoptysis and respiratory distress.<xref ref-type="bibr" rid="article-19045.r16">[16]</xref>&#x000a0;This is the only form of plague that can spread from person to person via aerosolized droplets.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In septicemic plague, patients develop&#x000a0;<italic toggle="yes">Yersinia pestis&#x000a0;</italic>bacteremia, disseminated intravascular coagulation, and gangrene of the extremities.&#x000a0;<xref ref-type="bibr" rid="article-19045.r17">[17]</xref></p>
          </list-item>
        </list>
        <p>The incubation period may be as long as 6 days or less than 1 day if a large quantity of&#x000a0;<italic toggle="yes">Y pestis</italic>&#x000a0;is inhaled; however, the average period is 2 to 3 days.<xref ref-type="bibr" rid="article-19045.r16">[16]</xref>&#x000a0;Mortality ranges from 40% in bubonic plague to nearly 100% in septicemic and pneumonic plague without treatment.<xref ref-type="bibr" rid="article-19045.r18">[18]</xref><bold>&#x000a0;</bold></p>
        <p>Plague should be suspected when a compatible epidemiological and clinical picture presents; confirmation is via at least 2 positive tests such as culture, PCR, or serum antibody detection performed in a level 3 or higher laboratory.<xref ref-type="bibr" rid="article-19045.r16">[16]</xref>&#x000a0;Patients with&#x000a0;<italic toggle="yes">Y pestis</italic>&#x000a0;infection require contact and droplet precautions. Streptomycin, ciprofloxacin,<xref ref-type="bibr" rid="article-19045.r19">[19]</xref>&#x000a0;doxycycline, and chloramphenicol can effectively treat plague.<xref ref-type="bibr" rid="article-19045.r20">[20]</xref><xref ref-type="bibr" rid="article-19045.r18">[18]</xref><xref ref-type="bibr" rid="article-19045.r21">[21]</xref><xref ref-type="bibr" rid="article-19045.r22">[22]</xref>&#x000a0;Plague is notifiable to public health officials.&#x000a0;</p>
        <p>
<bold>Brucellosis</bold>
</p>
        <p>Brucella species, ubiquitous gram-negative coccobacilli, cause brucellosis infections. Brucella is usually transmitted to humans from infected animals by contact or by consuming undercooked meat or unpasteurized dairy products. Person-to-person spread is rare; transmission through sexual contact and breastfeeding has been reported. Brucella are easily aerosolized, and few organisms are required to cause disease.&#x000a0;</p>
        <p>The incubation period of Brucellosis ranges from 5 days to 5 months.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/brucellosis/clinicians/suspected-infection.html">Brucellosis - Patients with Suspected Infection.</ext-link>&#x000a0;2012] Brucellosis begins as a flu-like illness, with headache, fever, and arthralgias. Patients can develop hepatomegaly, transaminitis, orchitis, epididymitis, endocarditis, and anemia. Symptoms can become chronic even with treatment. Neurobrucellosis occurs when meningitis or meningoencephalitis is present and is associated with optic neuritis, cerebellitis, ischemic strokes, myelitis,&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="33743640">[23]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="34669609">[24]</ext-link>&#x000a0;and chronic peripheral neuropathy, radiculopathy, or cranial nerve palsies.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="33287603">[25]</ext-link>&#x000a0;Death occurs in 2% of cases, with endocarditis being the most common cause.</p>
        <p>Diagnose Brucellosis by blood or cerebrospinal fluid cultures and treat with doxycycline plus either rifampin or streptomycin; sulfamethoxazole/trimethoprim may be used instead of doxycycline in children.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23906880">[26]</ext-link>&#x000a0;Brucellosis must be reported to public health in all states and territories.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/brucellosis/surveillance/index.html">Brucellosis - Surveillance.</ext-link>&#x000a0;2021]</p>
        <p>
<bold>Tularemia</bold>
</p>
        <p>Tularemia is caused by&#x000a0;<italic toggle="yes">Francisella tularensis,</italic>&#x000a0;a gram-negative facultative, intracellular coccobacillus spread primarily by arthropod vectors such as ticks; person-to-person spread has not been reported.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="32989563">[27]</ext-link>&#x000a0;The incubation period is typically 3 to 5 days, ranging from 1 to 21 days.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/tularemia/clinicians/index.html">[Tularemia - For Clinicians.</ext-link>&#x000a0;2022] The symptoms of tularemia include fever, headache, and fatigue, with others dependent on the route of exposure.</p>
        <p>Aerosolization of&#x000a0;<italic toggle="yes">F tularensis</italic>&#x000a0;for malicious purposes can lead to pneumonic, oropharyngeal, ulceroglandular, and oculoglandular tularemia. Pneumonic tularemia is the most severe, resulting from inhalational exposure; patients have respiratory symptoms and chest pain and can develop pleural effusions and mediastinitis. Oropharyngeal tularemia results from ingesting infected food and causes pharyngitis, fever, and cervical lymphadenopathy. Ulceroglandular tularemia is the most common and results from infection via broken skin or a vector bite; patients develop skin lesions and lymphadenopathy. Oculoglandular disease results in severe conjunctivitis from the contact of the conjunctiva with contaminated hands, water, or animal bodily fluids.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="32989563">[27]</ext-link></p>
        <p>Diagnose tularemia with an appropriate history and positive serology.&#x000a0;<italic toggle="yes">F tularensis</italic>&#x000a0;is difficult to culture, requiring a specific medium, trained lab technicians, and a biosafety level 3 laboratory.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/tularemia/clinicians/index.html">Tularemia - For Clinicians.</ext-link>&#x000a0;2022] Patients with suspected tularemia do not require isolation. Tularemia is a nationally reportable infectious disease.&#x000a0;&#x000a0;</p>
        <p>The antibiotic agent of choice for treatment depends on the patient and the severity of the disease:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="25207161">[28]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="24480622">[29]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="32989563">[27]</ext-link></p>
        <list list-type="bullet">
          <list-item>
            <p>Streptomycin and gentamicin: first-line for treating severe infections</p>
          </list-item>
          <list-item>
            <p>Doxycycline and ciprofloxacin: used in mild to moderate disease</p>
          </list-item>
          <list-item>
            <p>Gentamicin: the agent of choice in children</p>
          </list-item>
          <list-item>
            <p>Azithromycin: used for treating pregnant patients&#x000a0;</p>
          </list-item>
        </list>
        <p>Ciprofloxacin or doxycycline can be used for postexposure prophylaxis; vaccination is not generally available in the United States.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/tularemia/clinicians/index.html">Tularemia - For Clinicians.</ext-link>&#x000a0;2022]</p>
        <p>
<bold>Q Fever</bold>
</p>
        <p>Q fever is caused by&#x000a0;<italic toggle="yes">Coxiella burnetii&#x000a0;</italic>spread by ingestion, aerosolization, and tick vectors.&#x000a0;<italic toggle="yes">C burnetti</italic>&#x000a0;is easy to aerosolize and resistant to heat, drying, and many common disinfectants.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/qfever/healthcare-providers/index.html">Q Fever - Information for Healthcare Providers.</ext-link>&#x000a0;2019] Fewer than 10 organisms can cause infection. Transmission from person to person may rarely occur via the blood-borne route.&#x000a0;</p>
        <p>After an incubation period of 2 to 3 weeks,<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23535757">[30]</ext-link><bold>&#x000a0;</bold>the symptoms of Q fever include fever, chills, malaise, sweating, arthralgia, myalgia, cough, pleurisy, nausea, vomiting, and diarrhea. Roughly half of all people infected with C Burnett are asymptomatic. Acute Q fever is usually incapacitating rather than lethal, but pneumonia or myocarditis can lead to death. A post-Q fever fatigue syndrome affects up to 20% of patients with acute Q fever.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/qfever/healthcare-providers/index.html">Q Fever - Information for Healthcare Providers.</ext-link>&#x000a0;2019] Less than 5% of acute cases become chronic, most commonly presenting with endocarditis or osteomyelitis weeks to years after an acute infection.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23535757">[30]</ext-link><bold>&#x000a0;</bold>This condition is fatal if not treated.</p>
        <p>Q fever can be challenging to diagnose: the symptoms can be highly variable; serology can remain harmful for 7 to 15 days after onset of illness; and PCR is most sensitive within the first week, rapidly declining following appropriate antibiotic treatment.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/qfever/healthcare-providers/index.html">Q Fever - Information for Healthcare Providers.</ext-link>&#x000a0;2019] treatment must often be based on a presumptive diagnosis with later confirmation by a 4-fold increase in antibody titers.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="23535757">[30]</ext-link>&#x000a0;Acute Q fever is treated for 2 weeks with doxycycline, while chronic Q fever requires prolonged doxycycline plus hydroxychloroquine.<xref ref-type="bibr" rid="article-19045.r3">[3]</xref>[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/qfever/healthcare-providers/index.html">Q Fever - Information for Healthcare Providers.</ext-link>&#x000a0;2019]&#x000a0;</p>
        <p>Standard infection control procedures are adequate for patients with Q fever, except during aerosol-generating procedures. Q fever must be reported to local or state public health officials.&#x000a0;</p>
        <p>
<bold>Burkholderia</bold>
</p>
        <p><italic toggle="yes">Burkholderia mallei</italic>&#x000a0;causes glanders, a disease primarily of horses. Humans contract the disease extremely rarely by inhalation or contact of the organism with mucosal surfaces or breaks in the skin.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/glanders/index.html">Glanders.</ext-link>&#x000a0;2017] Localized infections appear 1 to 5 days at the contaminated site; dissemination occurs 1 to 4 weeks after infection.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/glanders/index.html">Glanders.</ext-link>&#x000a0;2017] Symptoms include fever, chills, night sweats, lymphadenopathy, headache, myalgias, tachypnea, nausea, vomiting, and diarrhea. Disseminated infections are usually fatal within 7 to 10 days without treatment. Even with treatment, mortality remains as high as 50%.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/glanders/index.html">Glanders.</ext-link>&#x000a0;2017] The recommended treatments for glanders are doxycycline, trimethoprim/sulfamethoxazole, and chloramphenicol.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="10923853">[31]</ext-link>&#x000a0;Diagnosis is by isolation of&#x000a0;<italic toggle="yes">B mallei</italic>.</p>
        <p>Patients with glanders require airborne precautions. While glanders is not a nationally notifiable disease, any unusual or cluster of infectious diseases should be reported to state or public health officials. Glanders has previously been used as a biological weapon and could be used again.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/glanders/index.html">Glanders.</ext-link>&#x000a0;2017]&#x000a0;&#x000a0;</p>
        <p>
<bold>Smallpox</bold>
</p>
        <p>Variola virus is a type of orthopoxvirus that causes smallpox. This disease was eradicated in 1980 thanks to a concerted worldwide vaccination campaign and is now officially restricted to labs in the United States and Russia; however, unsanctioned reserves likely exist.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="36624850">[32]</ext-link>&#x000a0;Variola virus is an ideal biological weapon because it is easily aerosolized, highly infectious, and transmissible from person to person.</p>
        <p>Smallpox is spread by airborne droplets or contact with body fluids. After an incubation period of 1 to 2 weeks, smallpox presents in 1 of 4 clinical forms: ordinary, modified, malignant, or hemorrhagic. Ordinary smallpox begins as a macular rash that progresses to pustules and then vesicles; lesions first present on the face and distal extremities and spread to the trunk. Unlike chickenpox, lesions in any part of the body progress simultaneously through the clinical stages.</p>
        <p>The initial diagnosis is based on the clinical presentation using 3 major and 5 minor criteria.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/smallpox/clinicians/algorithm-protocol.html">Evaluating Patients for Smallpox: Acute, Generalized Vesicular or Pustular Rash Illness Protocol</ext-link>. 2016]&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Major criteria:</p>
          </list-item>
        </list>
        <p>
<list list-type="order"><list-item><p>Febrile prodrome 1 to 4 days before the onset of rash with fever &#x0003e;101 &#x000b0;F (38.3 &#x000b0;C) and at least prostration, headache, backache, chills, vomiting, or severe abdominal pain</p></list-item><list-item><p>Classic smallpox lesions with deep-seated, firm, well-circumscribed vesicles or pustules</p></list-item><list-item><p>Lesions in the same stage of development on any one part of the body</p></list-item></list>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Minor criteria:</p>
          </list-item>
        </list>
        <p>
<list list-type="order"><list-item><p>Centrifugal distribution of lesions</p></list-item><list-item><p>First lesions on the oral mucosal surfaces, face, or forearms</p></list-item><list-item><p>Patient appears toxic&#x000a0;</p></list-item><list-item><p>Slow evolution of lesions from macule to papule to vesicle</p></list-item><list-item><p>Lesions on palms and soles</p></list-item></list>
</p>
        <p>Place patients suspected of having smallpox in airborne isolation. Immediately notify the Infection Prevention and Control team and the local or state health department. Real-time PCR testing is the preferred diagnostic test.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/smallpox/lab-personnel/specimen-collection/specimen-collection-transport.html">Smallpox - Specimen Collection and Transport Guidelines.</ext-link>&#x000a0;2017]</p>
        <p>The overall mortality of smallpox is approximately 30% in unvaccinated individuals. Smallpox vaccination within 72 hours of exposure can prevent the disease; vaccination within 3 to 7 days will not prevent the disease but will limit symptoms.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="26060872">[33]</ext-link>&#x000a0;Cidofovir is theorized to be a treatment for short-term prophylaxis against smallpox. Consult the CDC for treatment recommendations.</p>
        <p>
<bold>Ricin</bold>
</p>
        <p>Ricin is a naturally occurring protein of a class called toxalbumins found in the castor oil plant&#x000a0;<italic toggle="yes">Ricinus communis</italic>&#x000a0;seeds. Ricin is classified as a category B biological agent by the CDC. Exposure to ricin can occur via ingestion, inhalation, and subcutaneous and intravenous routes.</p>
        <p>Ricin inactivates ribosomes and causes toxicity by inhibiting protein synthesis. Both the A and B protein chains are required to cause toxicity; once ricin enters the body, chain B allows chain A to enter cells. Chain A then inhibits the 28S subunit of the 60S ribosome, effectively inhibiting protein translation and production.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30857127">[34]</ext-link></p>
        <p>The median lethal dose (LD50) of ricin toxin by inhalation in humans is 5 to 10 &#x003bc;g/kg. Symptoms of ricin toxicity include nausea, diarrhea, tachycardia, hypotension, and seizures. Depending on the route of exposure, onset may be immediate or delayed for a few hours. The diagnosis is made by clinical picture and finding the toxin in tissue samples by liquid chromatography-mass spectrometry or immunoassay. The treatment of ricin toxicity is supportive, as no antidote exists.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="26227025">[35]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="26449579">[36]</ext-link>&#x000a0;The poison control center, infection control practitioner, and local or state public health officials should immediately be contacted to ensure proper decontamination and to determine if a public health threat exists.[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://emergency.cdc.gov/agent/ricin/clinicians/control.asp">Ricin - Control Measures Overview for Responders and Clinicians.</ext-link>&#x000a0;2018]</p>
        <p>
<bold>Botulinum Toxin</bold>
</p>
        <p><italic toggle="yes">Clostridium botulinum&#x000a0;</italic>is a spore-forming, anaerobic, gram-positive bacteria that produces botulinum toxin, also known as botulinum neurotoxin or BoNT. BoNT is a category A biological agent. BoNT consists of a light and heavy chain; the heavy chain is responsible for transporting the light chain into the neuron, while the light chain contains the enzyme that cleaves target proteins. The 7 main BoNT serotypes, A through G, have multiple subtypes. Clinical symptoms are similar between the different serotypes. More recently discovered variants challenge botulinum nomenclature; BoNT/H resembles subtypes A and F and is alternately called BoNT/FA or BoNT/HA and has lower potency with a slower progression of clinical symptoms.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29748471">[37]</ext-link>&#x000a0;</p>
        <p>BoNT functions by inhibiting the release of acetylcholine at the neuromuscular junction. Once taken up into the neuron, the light chain targets components of the SNARE (soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptor) complex, which is responsible for vesicular trafficking and neurotransmitter release. Serotypes A, C, and E cleave SNAP-25 (synaptosomal-associated protein of 25-kDa), while serotypes B, D, F, and G cleave syntaxin. The cleavage of these proteins disrupts neurotransmitter release, and signals cannot be transmitted across neuronal synapses.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30857127">[34]</ext-link></p>
        <p>BoNT exposure can occur via inhalation, ingestion, or parenteral routes. Botulism causes descending flaccid paralysis, initially affecting bulbar muscles, with progression to involve skeletal and respiratory muscles. Initial symptoms occur within a few to 36 hours of poisoning&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="30857127">[34]</ext-link>&#x000a0;and include dysphagia, blurry vision, and speech difficulties.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="33956777">[38]</ext-link>&#x000a0;Death may occur due to respiratory arrest from paralysis of the respiratory muscles.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="28265441">[39]</ext-link>&#x000a0;BoNT has an LD50 of 1 ng/kg in mice. When inhaled, the lethal dose in a 70 kg human is 0.7 to 0.9 ug or 70 ug if ingested.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="10675154">[40]</ext-link>&#x000a0;</p>
        <p>Clinical criteria are available to aid the diagnosis of botulism as this condition is commonly misdiagnosed as myasthenia gravis, Guillain-Barre syndrome, intoxication, or psychiatric conditions.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="33956777">[38]</ext-link>&#x000a0;Administering botulism antitoxin as soon as possible and preferably within 24 hours of symptom onset is critical.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="33956777">[38]</ext-link>&#x000a0;Antitoxin does not reverse paralysis but will prevent its progression. Treatment is otherwise supportive; prolonged mechanical ventilation may be necessary.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="26227025">[35]</ext-link></p>
        <p>Botulinum antitoxin can be obtained via contact with local state health departments and through the CDC via their hotline at 770-488-7100.</p>
      </sec>
      <sec id="article-19045.s5" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Once a patient has been diagnosed with an illness potentially due to a biological weapon, communication with the interprofessional healthcare team, including clinicians, nurses, pharmacists, and public health officials, should occur. Adequate decontamination of the patient and appropriate precautions for first responders and hospital staff to avoid additional casualties or the spread of contagious diseases are priorities. In attacks involving many people, communication with hospital leadership and government officials is required to access medical supply stockpiles and mobilize human and other resources to treat large numbers of patients.</p>
        <p>Training and education before biological warfare events, when emotions are calm and resources adequate, are more effective than just-in-time training after an event. Healthcare staff must clearly understand the available resources and anticipated demands on those resources in large-scale events.</p>
        <p>The relatively recent use of ricin and anthrax as bioterrorism agents demonstrates how even small-scale attacks quickly become international news. Healthcare providers may need to communicate with law enforcement agencies, members of the media, and elected officials.</p>
      </sec>
      <sec id="article-19045.s6">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19045&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19045">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19045/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19045">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19045.s7">
        <title>References</title>
        <ref id="article-19045.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oliveira</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mason-Buck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ballard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Branicki</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Amorim</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biowarfare, bioterrorism and biocrime: A historical overview on microbial harmful applications.</article-title>
            <source>Forensic Sci Int</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>314</volume>
            <fpage>110366</fpage>
            <pub-id pub-id-type="pmid">32683271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barras</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Greub</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>History of biological warfare and bioterrorism.</article-title>
            <source>Clin Microbiol Infect</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>497</fpage>
            <page-range>497-502</page-range>
            <pub-id pub-id-type="pmid">24894605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f5;hmus</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Janse</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>van de Goot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Rotterdam</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Rodents as potential couriers for bioterrorism agents.</article-title>
            <source>Biosecur Bioterror</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>11 Suppl 1</volume>
            <fpage>S247</fpage>
            <page-range>S247-57</page-range>
            <pub-id pub-id-type="pmid">23971813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hart</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Ketai</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Armies of pestilence: CNS infections as potential weapons of mass destruction.</article-title>
            <source>AJNR Am J Neuroradiol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1018</fpage>
            <page-range>1018-25</page-range>
            <pub-id pub-id-type="pmid">25477355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Bokor</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Bioterrorism: pathogens as weapons.</article-title>
            <source>J Pharm Pract</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>521</fpage>
            <page-range>521-9</page-range>
            <pub-id pub-id-type="pmid">23011963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedlander</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Management of potential bioterrorism-related conditions.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Jun</month>
            <day>04</day>
            <volume>372</volume>
            <issue>23</issue>
            <fpage>2272</fpage>
            <pub-id pub-id-type="pmid">26039617</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erenler</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>G&#x000fc;zel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baydin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>How Prepared Are We for Possible Bioterrorist Attacks: An Approach from Emergency Medicine Perspective.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>7849863</fpage>
            <pub-id pub-id-type="pmid">30104916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christian</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Biowarfare and bioterrorism.</article-title>
            <source>Crit Care Clin</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>717</fpage>
            <page-range>717-56</page-range>
            <pub-id pub-id-type="pmid">23830660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zasada</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Injectional anthrax in human: A new face of the old disease.</article-title>
            <source>Adv Clin Exp Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-558</page-range>
            <pub-id pub-id-type="pmid">29533547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweeney</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hicks</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eichacker</surname>
                <given-names>PQ</given-names>
              </name>
            </person-group>
            <article-title>Anthrax infection.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2011</year>
            <month>Dec</month>
            <day>15</day>
            <volume>184</volume>
            <issue>12</issue>
            <fpage>1333</fpage>
            <page-range>1333-41</page-range>
            <pub-id pub-id-type="pmid">21852539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sirisanthana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Anthrax of the gastrointestinal tract.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>649</fpage>
            <page-range>649-51</page-range>
            <pub-id pub-id-type="pmid">12095428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guarnizo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meaney-Delman</surname>
                <given-names>D</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2015</year>
            <month>Dec</month>
            <day>04</day>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>1</fpage>
            <page-range>1-22</page-range>
            <pub-id pub-id-type="pmid">26632963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inglesby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>O'Toole</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ascher</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Eitzen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Friedlander</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gerberding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McDade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Osterholm</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Tonat</surname>
                <given-names>K</given-names>
              </name>
              <collab>Working Group on Civilian Biodefense</collab>
            </person-group>
            <article-title>Anthrax as a biological weapon, 2002: updated recommendations for management.</article-title>
            <source>JAMA</source>
            <year>2002</year>
            <month>May</month>
            <day>01</day>
            <volume>287</volume>
            <issue>17</issue>
            <fpage>2236</fpage>
            <page-range>2236-52</page-range>
            <pub-id pub-id-type="pmid">11980524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bower</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Schiffer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Atmar</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Keitel</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Friedlander</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>K</given-names>
              </name>
              <collab>ACIP Anthrax Vaccine Work Group</collab>
            </person-group>
            <article-title>Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2019</year>
            <month>Dec</month>
            <day>13</day>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">31834290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zietz</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Dunkelberg</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The history of the plague and the research on the causative agent Yersinia pestis.</article-title>
            <source>Int J Hyg Environ Health</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>207</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-78</page-range>
            <pub-id pub-id-type="pmid">15031959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Plague: Recognition, Treatment, and Prevention.</article-title>
            <source>J Clin Microbiol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29070654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riedel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Plague: from natural disease to bioterrorism.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-24</page-range>
            <pub-id pub-id-type="pmid">16200159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stock</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>[Yersinia pestis and plague - an update].</article-title>
            <source>Med Monatsschr Pharm</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>441</fpage>
            <page-range>441-8; quiz 449</page-range>
            <pub-id pub-id-type="pmid">25643450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Apangu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abaru</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Candini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Apio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Okoth</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Okello</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaggwa</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Acayo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ezama</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yockey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schriefer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mbidde</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Mead</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Human Plague with Oral Ciprofloxacin.</article-title>
            <source>Emerg Infect Dis</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>553</fpage>
            <page-range>553-5</page-range>
            <pub-id pub-id-type="pmid">28125398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pechous</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Sivaraman</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stasulli</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>WE</given-names>
              </name>
            </person-group>
            <article-title>Pneumonic Plague: The Darker Side of Yersinia pestis.</article-title>
            <source>Trends Microbiol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>190</fpage>
            <page-range>190-197</page-range>
            <pub-id pub-id-type="pmid">26698952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raoult</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mouffok</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bitam</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Piarroux</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Drancourt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Plague: history and contemporary analysis.</article-title>
            <source>J Infect</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>66</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-26</page-range>
            <pub-id pub-id-type="pmid">23041039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19045.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wendte</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ponnusamy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reiber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Clinkenbeard</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>55</volume>
            <issue>8</issue>
            <fpage>3752</fpage>
            <page-range>3752-7</page-range>
            <pub-id pub-id-type="pmid">21628541</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
